BRCA1 and BRCA2 were significant genes in ovarian cancer (BRCA1, RR of AI events in samples with RDGVs compared to without RDGVs = 23.3, 94.1% of patients with RDGVs also have AI versus 53.1% of patients without RDGVs, P < 2.0 × 10−6; for BRCA2, RR = 4.7, 83.3% versus 49.3%, P < 9.3 × 10−4) and in breast cancer (BRCA1, RR = 2.5, 48.6% versus 26.6%, P < 4.6 × 10−3; BRCA2, RR = 3.6, 57.1% versus 27.9%, P < 1.3 × 10−3). The gene discussed is BRCA2; the disease is ovarian cancer.